"Combination Therapy Shows Promise in Advanced Biliary Tract Cancer Treatment"

Pembrolizumab, an immune checkpoint inhibitor, in combination with gemcitabine and cisplatin, has been found to improve overall survival in patients with advanced biliary tract cancer compared to gemcitabine and cisplatin alone, according to a phase 3 trial. The study involved 1,069 patients and found that the pembrolizumab group had a median overall survival of 12.7 months compared to 10.9 months in the placebo group. The combination therapy could be a new treatment option for patients with previously untreated metastatic or unresectable biliary tract cancer.